Aug 20, 2025 • Benzinga
NEUTRAL
Why Is Celldex Therapeutics Stock Falling Today - Celldex Therapeutics ( NASDAQ:CLDX )
Barzolvolimab cut mast cells by -36 vs. -2.7 in placebo at 12 weeks. Despite cell depletion, no symptom or endoscopic improvement in eosinophilic esophagitis. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here →
Aug 20, 2025 • Benzinga
NEUTRAL
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Celldex Therapeutics ( NASDAQ:CLDX ) , Alcon ( NYSE:ALC )
U.S. stock futures were slightly lower this morning, with the S&P 500 futures falling around 0.1% on Wednesday. Shares of La-Z-Boy Incorporated LZB fell sharply in pre-market trading as the company reported weaker-than-expected financial results for the first quarter of fiscal 2026.
Aug 20, 2025 • Benzinga
NEUTRAL
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Color Star Tech ( NASDAQ:ADD ) , Aspen Insurance Hldgs ( NYSE:AHL )
Shares of Rocket Pharmaceuticals, Inc. RCKT rose sharply in pre-market trading after the company disclosed that the FDA has lifted the clinical hold on the pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease. Rocket Pharmaceuticals shares jumped 15.8% to $3.37 in the pre-market ...
Aug 19, 2025 • GlobeNewswire
NEUTRAL
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis ( EoE )
HAMPTON, N.J., Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) today reported topline results from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis ( EoE ) , a chronic inflammatory disease of the esophagus.
Aug 07, 2025 • Zacks Commentary
NEUTRAL
Celldex Therapeutics ( CLDX ) Reports Q2 Loss, Misses Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of +1.16% and -56.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 25, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
scPharmaceuticals ( SCPH ) Soars 8.8%: Is Further Upside Left in the Stock?
scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.